Genflow Biosciences plc has announced a development program in ophthalmology focused on advancing a novel gene therapy leveraging its proprietary centenarian SIRT6 (cSIRT6).

Genflow Biosciences Signs MSA with Heureka Labs, Launching AI-Powered Partnership in Gene Therapy Research LONDON, UNITED KINGDOM / ACCESS Newswire / April 14, 2025 / Genflow Biosciences Plc (LSE:GENF ...

This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several ...

This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several ...